Author's response

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 18, 2013, Pages 2612-2613

  Gouni Berthold, Ioanna ^a   Mikhailidis, Dimitri P ^b   Rizzo, Manfredi ^c,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF PALERMO   (Italy)

^d Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; MONOTHERAPY; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; HUMANS; HYPERCHOLESTEROLEMIA; SIMVASTATIN;

EID: 84887973666     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.849063     Document Type: Letter

References (10)

1. Doggrell SA. Clinical benefits of ezetimibe; absence of proof is just that. Expert Opin Pharmacother 2013; In press
2. Doggrell SA. The ezetimibe controversy-can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together? Expert Opin Pharmacother 2012;13:1469-80
3. Patel AY, Pillarisetti J, Marr J, Vacek JL. Ezetimibe in combination with a statin does not reduce all-cause mortality. J Clin Med Res 2013;5:275-80
4. Lin CF, Gau CS, Wu FL, et al. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: A 3-year populationbased retrospective cohort study in Taiwan. Clin Ther 2011;33:1120-31
5. Hayek S, CanepaEscaro F, Sattar A, et al. Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 2013;111:532-9
6. Gouni-Berthold I, Mikhailidis DP, Rizzo M. Clinical benefits of ezetimibe use: Is absence of proof, proof of absence? Expert Opin Pharmacother 2012;13:1985-8
7. Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: The end of a misunderstandinǧ Curr Vasc Pharmacol 2011;9:381-4
8. Fleg JL, Mere M, Howard BV, et al. Effects of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetic Study) trial. J Am Coll Cardiol 2008;52:2198-205
9. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009;49:838-47
10. Nordestgaard BG, Chapman MJ, Humphries SE, et al. for the European Atherosclerosis Society Consensus. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; Epub ahead of print